Dupixent
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Dupixent in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Dupixent.
6
Global Revenue Ranking
3
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Dupixent
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
The inflammatory skin condition affects over 26 million people in the US
Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease
These are the first clinical study results for the drug in a large population of patients with darker skin tones
The company is the latest major drugmaker to announce a significant investment in the country
More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease
Approximately 27,000 adults in the US are living with uncontrolled cases of the skin disease
Dupixent is now the first drug in the EU indicated for use in this patient population
Approximately 300,000 patients in the US will be eligible for the therapy
If approved, Dupixent would be the first drug in the EU indicated for this patient population
Approximately 9,000 adolescents in the US are living with inadequately controlled cases of the chronic disease
Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology